Ultragenyx Pharmaceutical Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on August 2, 2018. The report serves as a Regulation FD disclosure to provide the prepared remarks for the company's earnings call regarding financial results for the three and six months ended June 30, 2018. The filing was necessitated by audio quality issues during the live earnings call.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a conduit for the earnings call script (Exhibit 99.1) rather than containing the financial data directly within the 8-K body.
Material Changes
No material changes to financial performance or operations are detailed in this specific filing text. The document references the existence of results for the period ended June 30, 2018, but does not quantify changes versus prior periods.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information provided under Item 7.01 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference. No specific guidance, outlook, or risk factors are enumerated in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Call Script) attached to this filing for actual financial figures and management commentary.
- Verify the specific revenue and net loss figures for the three and six months ended June 30, 2018, in the referenced script.
- Check for any forward-looking statements or updated guidance provided during the earnings call.
- Confirm the company's cash position and burn rate as discussed in the call remarks.